REGN 3470/3471/3479

Drug Profile

REGN 3470/3471/3479

Alternative Names: REGN-EB3; REGN3470-3471-3479

Latest Information Update: 12 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Antibodies; Antivirals
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ebola virus infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Ebola virus infections

Most Recent Events

  • 03 Jul 2018 Regeneron Pharmaceuticals initiates an expanded access trial for Ebola virus infections (NCT03576690)
  • 31 May 2018 Pharmacodynamics data from a preclinical studies in Ebola virus infections released by Regeneron Pharmaceuticals
  • 29 May 2018 REGN 3470/3471/3479 receives Orphan Drug status for Ebola virus infections (Combination therapy) in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top